Pulished Date October, 2018
ID: 7712
Share on
Share on

Middle-East & Africa Cardiovascular Therapeutic Drugs By Disease (Arteriosclerosis, Cardiac Arrhythmias, Myocardial Infarction, Acute Coronary Syndrome, Peripheral Artery Disease, Coronary Artery Disease, Hypertension, Hyperlipidaemia, Thrombosis, Cardiac Failure Diseases And Other Cardiovascular Diseases), By Drug Class (monotherapies And Combination) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecast (2018 - 2023)

Pulished: October, 2018
ID: 7712
Pages: 145

Middle-East & Africa Cardiovascular Therapeutic Drugs Market is estimated to be USD 7.95 billion in 2018 and is poised to reach USD 9.02 billion by 2023 growing at a CAGR of 2.55%. The past several decades have witnessed huge success in the development of effective drug therapies for common cardiovascular disease. These therapies have been widely used with the rising prevalence of cardiovascular diseases resulting in the increased market for cardiovascular therapeutics.

Cardiovascular therapeutics drugs refers to the prescribed medicines and drugs for the diseases which are related to the functioning and treatment of heart and blood vessels. While cardiovascular diseases remains to be the leading cause of dead, the major reason causing cardiovascular problems include heart failure, blood clots, coronary artery diseases, high cholesterol and others.

Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. The driving factors for the cardiovascular therapeutics includes growing per capita medical spending, rising aging population and epidemic of general medical problems which includes obesity and diabetes. However, there are few restraints faced by the market which includes high costs involving drug development and lowering of target population. Cardiovascular diseases remains the common cause of mortality and morbidity across the globe and is an emerging threat. Despite its extensive existence, many of the drug development pipelines has been stagnant for variety of factors.

Middle-East & Africa cardiovascular therapeutic drugs market is segmented based on the type of disease and drug class. The market based on the disease is further segmented into Arteriosclerosis, Cardiac arrhythmias, Myocardial infarction, acute coronary syndrome, Peripheral artery disease, Coronary artery disease, hypertension, hyperlipidaemia, thrombosis, cardiac failure diseases and other cardiovascular diseases. Based on the drug class, the market is segmented into monotherapies and combination drug classes. Based on geography, market is segmented into Saudi Arabia, UAE, Israel, Africa and others.

Some of the leading companies in Cardiovascular Therapeutics Drugs Market includes Johnson & Johnson, Bayer, AstraZeneca, Novartis, Bristol-Myers Squibb, Takeda, Merck, Pfizer Sanofi, and boehringer ingelheim.

1. Introduction                 

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

2. Research Methodology                           

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

3. Overview                       

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                    

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

5. Market Segmentation                              

                5.1 By Disease  

                                5.1.1 Arteriosclerosis

                                5.1.2 Cardiac arrhythmias

                                5.1.3 Myocardial infarction

                                5.1.4 Acute Coronary Syndrome

                                5.1.5 Peripheral artery disease

                                5.1.6 Coronary artery disease

                                5.1.7 Hypertension

                                5.1.8 Hyperlipidaemia

                                5.1.9 Thrombosis

                                5.1.10 Cardiac failure diseases

                                5.1.11 Others

                5.2 By Drug Class             

                                5.2.1 Monotherapies

                                5.2.2 Combination Therapies

6. Geographical Analysis                              

                6.1 Introduction               

                6.2 Middle-East                

                6.3 Africa            

7. Pipeline Product Analysis                 

                7.1 Overview          

                7.2 Pipeline Development Landscape         

                7.3 Molecular Targets in the Pipeline          

                7.4 Clinical Trials           

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.

8. Strategic Analysis                       

                8.1 PESTLE analysis         

                                8.1.1 Political

                                8.1.2 Economic

                                8.1.3 Social

                                8.1.4 Technological

                                8.1.5 Legal

                                8.1.6 Environmental

                8.2 Porter’s Five analysis              

                                8.2.1 Bargaining Power of Suppliers

                                8.2.2 Bargaining Power of Consumers

                                8.2.3 Threat of New Entrants

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry

9. Market Leaders' Analysis                        

                9.1 AstraZeneca               

                                9.1.1 Overview

                                9.1.2 Product Analysis

                                9.1.3 Strategic Evaluation and Operations

                                9.1.4 Financial analysis

                                9.1.5 Legal issues

                                9.1.6 Recent Developments

                                9.1.7 SWOT analysis

                                9.1.8 Analyst View

                9.2 Novartis       

                9.3 Bristol-Myers Squibb              

                9.4 Pfizer            

                9.5 Sanofi           

                9.6 Merck           

                9.7 Bayer            

                9.8 Takeda         

                9.9 Boehringer Ingelheim            

                9.10 Johnson & Johnson              

10. Competitive Landscape                         

                10.1 Market share analysis          

                10.2 Merger and Acquisition Analysis     

                10.3 Agreements, collaborations and Joint Ventures      

                10.4 New Product Launches       

11. Expert Opinions                        

                11.1 Market Outlook     

                11.2 Investment Opportunities 

Appendix                           

                a) List of Tables

                b) List of Figures              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Cardiovascular Therapeutic Drugs Market By Region, From 2018-2023 (USD billion)                                                             
  2. Middle East & Africa Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                           
  3. Middle East & Africa Arteriosclerosis Market By Region, From 2018-2023 (USD billion)                                                   
  4. Middle East & Africa Cardiac arrhythmias Market By Region, From 2018-2023 (USD billion)                                                          
  5. Middle East & Africa Myocardial infarction Market By Region, From 2018-2023 (USD billion)                                                        
  6. Middle East & Africa Acute Coronary Syndrome Market By Region, From 2018-2023 (USD billion)                                                             
  7. Middle East & Africa Peripheral artery disease Market By Region, From 2018-2023 (USD billion)                                                
  8. Middle East & Africa Coronary artery disease Market By Region, From 2018-2023 (USD billion)                                                  
  9. Middle East & Africa Hypertension Market By Region, From 2018-2023 (USD billion)                                                       
  10. Middle East & Africa Hyperlipidaemia Market By Region, From 2018-2023 (USD billion)                                                 
  11. Middle East & Africa Thrombosis Market By Region, From 2018-2023 (USD billion)                                                           
  12. Middle East & Africa Cardiac failure diseases Market By Region, From 2018-2023 (USD billion)                                                   
  13. Middle East & Africa Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                      
  14. Middle East & Africa Monotherapies Market By Region, From 2018-2023 (USD billion)                                                   
  15. Middle East & Africa Combination Therapies Market By Region, From 2018-2023 (USD billion)                                                   
  16. Middle East Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                              
  17. Middle East Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                         
  18. Africa Cardiovascular Therapeutic Drugs Market By Disease, From 2018-2023 (USD billion)                                                          
  19. Africa Cardiovascular Therapeutic Drugs Market By Drug Class, From 2018-2023 (USD billion)                                                     

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients

Research Areas